Elevated serum concentrations of the vasoactive protein ET-1 occur in the setting of systemic inflammatory response syndrome and contribute to distal organ hypoperfusion and pulmonary hypertension. Thus, understanding the cellular source and transcriptional regulation of systemic inflammatory stress-induced ET-1 expression may reveal therapeutic targets. Using a murine model of LPS-induced septic shock, we demonstrate that the hepatic macrophage is the primary source of elevated circulating ET-1, rather than the endothelium as previously proposed. Using pharmacologic inhibitors, ET-1 promoter luciferase assays, and by silencing and overexpressing NFκB inhibitory protein IκB expression, we demonstrate that LPS-induced ET-1 expression occurs via an NFκB dependent pathway. Finally, the specific role of the cRel/p65 inhibitory protein IκBβ was evaluated. Although cytoplasmic IκBβ inhibits activity of cRel containing NFκB dimers, nuclear IκBβ stabilizes NFκB/DNA binding and enhances gene expression. Using targeted pharmacologic therapies to specifically prevent IκBβ/NFκB signaling, as well as mice genetically modified to overexpress IκBβ, we show that nuclear IκBβ is both necessary and sufficient to drive LPS-induced ET-1 expression. Together, these results mechanistically link the innate immune response mediated by IκBβ/NFκB to ET-1 expression and potentially reveals therapeutic targets for patients with gram-negative septic shock.